Is rapid nucleic acid testing of new crown still necessary for the launch of new crown effective drugs?
Recently, the Director-General of WHO said in a press conference that 2022 must end the New Crown pandemic in order to accelerate the process of New Crown pneumonia prevention and control, to achieve an early end to the New Crown epidemic, and to accelerate the achievement of sustainable development goals.
With 50,000 deaths per week from NCC and the rapid spread of the Omicron mutant strain, the goal of ending the NCC pandemic must be achieved. And this "goal" requires the joint efforts of all countries. Recently, China has delivered a high score on the "effective drug".
Recently, China's first anti-neo-coronavirus drug was approved by the Drug Administration for marketing. R & D team leader, Professor Zhang Linqi, Tsinghua University School of Medicine, said: this special drug may be able to turn the new crown into a common cold, through the clinical trials carried out in a number of countries clinical trial sites, have proved its safety, effectiveness, to reduce the hospitalization rate and mortality rate of more than 80%.
The mechanism of action is to select two strains of antibodies with strong blocking power against the new crown virus, the strongest antiviral ability, two antibodies for synergistic action, if one of them is escaped, the other antibody can fight completely independently to increase the sniping effect of the antibody on the virus.
In the face of the WHO's determination to terminate the new crown and the birth of an effective drug, is the rapid nucleic acid test for the new crown no longer necessary?
No! Prof. Zhang Linqi gave a detailed explanation of the population for the use of specific drugs: specific drugs are mainly for infected patients and are mainly therapeutic in nature. That is to say, unlike vaccines, they have no direct protective effect on uninfected people. For the uninfected population, personal protection measures are still a top priority. The status of rapid nucleic acid testing in outbreak prevention and control remains unshakable.
However, with the normalization of the epidemic, there are bound to be new developments in rapid nucleic acid testing.
Since NIV and influenza are respiratory viruses, both viruses are RNA viruses and their symptoms are similar. In the future of "new crown" and "flu" coexistence, new crown nucleic acid rapid test will change from a single project single test to multiplex test. The so-called multiplex test is to detect multiple viruses at one time, so as to realize the possibility of screening multiple infections at one time. At present, companies in the IVD industry have invested very large resources and costs in the research and development of related projects.
However, at present, rapid nucleic acid detection of new crown is still the focus of our prevention and control. Now, when new crown is still more powerful than influenza, new crown virus and single test are still the mainstream.
And efficient amplification reagents as well as portable amplifiers are still the main strength of fever clinics!
Besides, in the epidemic prevention and control, the technical upgrade and iteration of nucleic acid extraction instruments, sample pre-processing instruments, and amplification instruments are also still the focus of the neo-crown epidemic period!
